BMO Capital Downgrades Amylin Pharmaceuticals (AMLN) to Market Perform

March 4, 2011 7:13 AM EST Send to a Friend
BMO Capital downgraded Amylin Pharmaceuticals (NASDAQ: AMLN) from Outperform to Market ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login